



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 35/78	A2	(11) International Publication Number: WO 96/37210 (43) International Publication Date: 28 November 1996 (28.11.96)
(21) International Application Number: PCT/NL96/00210 (22) International Filing Date: 24 May 1996 (24.05.96) (30) Priority Data: 950075 26 May 1995 (26.05.95) MK 950076 26 May 1995 (26.05.95) MK (71) Applicant (for all designated States except US): ROPAPHARM B.V. I.O. [NL/NL]; Elementenstraat 19-21, NL-1014 AR Amsterdam (NL). (72) Inventor; and (75) Inventor/Applicant (for US only): NINKOV, Dusan [-/NL]; Punter 14, NL-1186 RC Amstelveen (NL). (74) Agent: DE BRUIJN, Leendert, C.; Nederlandsch Octrooibu- ureau, Scheveningseweg 82, P.O. Box 29720, NL-2502 LS The Hague (NL).	(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: PHARMACEUTICAL COMPOSITIONS, BASED ON ETHERIC OILS OBTAINED FROM PLANTS FOR USE IN THE HUMAN AND VETERINARY MEDICAL FIELD		
(57) Abstract <p>The invention relates to pharmaceutical compounds which are based on the anti-inflammatory properties of etheric oils selected from the group consisting of <i>Origanum vulgare</i>, <i>Thymus vulgaris</i>, <i>Mentha piperita</i>, <i>Thymus serpyllum</i>, <i>Saturea hortensis</i>, <i>Saturea montana</i>, <i>Saturea subricata</i>, <i>Carum corticum</i>, <i>Thymus zygis</i>, <i>Ocimum gratissimum</i>, <i>Moranda pungata</i>, <i>Mosla japonica</i> and <i>Salvia officinalis</i>. Preferably the etheric oils, obtained at the distillation of <i>Origanum vulgare</i>, <i>Thymus vulgaris</i> and/or <i>Mentha piperita</i> are used. Such pharmaceutical compounds, compared to synthetic sulfonamids, antibiotics and cortisones do not create biorecipients in the human body as well as in animal meat and milk and do not contribute to the resistance of microorganism against pharmaceutical compositions in general. The composition according to the invention can be used in the treatment of colibacillosis, dermatomycosis, lice, perspiration and fungus on feet, dermatitis, acne and of veterinary diseases like coccidiosis, mastitis, etc.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

Pharmaceutical compositions, based on etheric oils obtained from plants for use in the human and veterinary medical field.

Description

5

Field of technology

The invention relates to pharmaceutical compositions, comprising etheric oils extracted from specific plants, a process for preparing such pharmaceutical compositions, as well as to the application of said compositions in the human and veterinary medical field.

Technical problems solved with this invention

One of the technical problems that is solved with this invention is the obtainment of various types of human medicaments on the basis of active natural components that successfully replace prior art medicaments based on sulfonamids, antibiotics, cortisones etc., whereby the new products according to the invention:

1. do not create biorecidives in the human body;
2. do not generate resistance of microorganisms;
3. are ecologically unsuspected; and
4. are not toxic, mutagenic or teratogenic.

Another problem that is solved with this invention is the obtainment of various types of veterinary medicaments on the basis of natural components, that successfully replace prior art products based on sulfonamids, antibiotics etc.. The application of the active substances according to the invention eliminates many unwanted effects caused by the prior art products like sulfonamids and antibiotics, such as:

1. the presence of biorecidives in the meat and milk of animals treated with such products; and
2. the aquirement of resistance of microorganisms-bacteria against the prior art products.

Description of the prior art

In the prior art known medicaments for curing human diseases like: cholera, colibacillosis, dermatomycosis, inflammation of the

oral mucosa and pharynx, fungicidal and bacteriological infections, inflammation of the mucous membrane of the vagina, colitis, various etiologies, the treatment of festered wounds, are based on active substances that have an antibiotic, sulfonamid or hormonal corticoid origin.

The tendencies of modern science are to substitute a part of the medicaments based on such origins by ecologically healthy drugs, which are much easier for the human organism to bear and have a much more beneficial influence on human health.

The same counts for veterinary medicaments based on antibiotics, sulfonamids and even hormones for treating animal diseases such as cholera, different types of colibacillosis, dermatomycosis, inflammation of the udder, inflammation of the vagina and uterus, various etiologies and coccidiosis. In order to avoid the unwanted consequences mentioned above, it is necessary to have ecologically healthy and unsuspected products for treating above veterinary diseases.

More in particular a great deal of the bacteria that cause the abovementioned diseases have developed a form of resistance against the prior art medicaments, so the products according to the invention resolve the problems of treating the diseases listed above, as well as various types of diarrhea, inflammation of the abdomen, gastritis, inflammation of the oral mucosa, inflammation of the ear, conjunctivitis, etc.

Description of the solution to the above-described problem.

The primary component which is applied in the pharmaceutical compositions according to the invention is etheric oil obtained from any of the following plants: *Origanum vulgare*, *Thymus vulgaris*, *Mentha piperita*, *Thymus serpyllum*, *Saturea hortensis*, *Saturea montana*, *Saturea subricata*, *Carum corticum*, *Thymus zygis*, *Ocimum gratissimum*, *Moranda pungtata*, *Mosla japonica* and *Salvia officinalis*. Preferably the etheric oil is obtained from any of the following plants: *Origanum vulgare*, *Thymus vulgaris* and *Mentha piperita*. Most preferably the etheric oil is at least obtained from *Origanum vulgare* and optionally from *Thymus vulgaris*.

In case of veterinary medicaments it is also possible to use

synthetic thymol having the chemical name isopropylcresol. Further the compound tannin may be used in veterinary compositions. This tannin can be recovered by extracting the residu of the leaves and blossoms of the *Origanum vulgare* plants obtained after the etheric oil-distillation (see below).

The pharmaceutical compositions according to the invention may comprise a pharmaceutically acceptable carrier, preferably of natural origin. Representatives of such carriers are generally known in the human and veterinary pharmaceutical field. Examples of such carriers are lactose, honey, laurel, vaselin, paraffin, starch products, calcium carbonate, etc.

The pharmaceutical compositions may have any form suitable for its application, for instance the form of a capsule, syrup, tincture, ointment, powder, emulsion, paste, etc.

The content of active agent in the pharmaceutical compositions according to the invention, which in fact does also depend on its pharmaceutical use, may vary between wide limits. Preferably the active agent is present in an amount of 1-15% by weight, most preferably 4-10% by weight, calculated on the total weight of the pharmaceutical composition.

Further to the active agent according to the invention also other active substances, preferably of natural origin, can be used. Such substances may have bacteriological, fungicidal, adstringic etc. properties.

The following dosage of a pharmaceutical composition, comprising 5% by weight of oil from *Origanum vulgare* and 95% by weight of calcium carbonate in powder form may be applied for mass and individual treatment:

A) Mass treatment:

Preventive dose:

pigs, rabbits, calves:

500 g of powder per ton of feed

chickens, ducks, turkies:

450 g of powder per ton of feed

Therapeutical dose:

pigs, rabbits, calves:

1000 g of powder per ton of feed

5

chickens, ducks, turkies:

900 g of powder per ton of feed for 7-10 days of therapy.

B) Individual treatment:

calves, foals:

10

0.20 - 0.25 g per kg of body weight

piglets, lambs, kids:

0,10 g per kg of body weight

15

For illustrating the pharmaceutical activity of etheric oil from *Origanum vulgare* (origanum oil) the following "antibiogram" of origanum oil is illustrated in Table A:

TABLE A

	Microorganisms	Intensity of Effect
5	Staphylococcus aureus	+++
	Treponema hyodisaenteriae	++++
	Erysipelothrix insidiosa	+++
	Pasteurella multocida	++++
	Streptococcus faecalis	+++
10	Streptococcus agalactiae	+++
	Proteus mirabilis	+++
	Proteus vulgaris	+++
	Proteus rettgeri	+++
	Escherichia coli	++++
15	Vibrio coli	++++
	Salmonella spp.	++++
	Streptococcus pyogenes anim.C	+++
	Klebsiella pneumoniae	+++
	Enterobacter aerogenes	+++
20	Corynebacterium pyogenes	+++
	Streptococcus uberis	+++
	Candida spp.	+++
	Pseudomonas aeruginosa	+++
	Mycobacterium tuberculosis	++++
25	Aspergillus spp.	++++
	Mucor spp.	+++
	Cryptosporidia spp.	++++
	Eimeria spp. (coccidiosis)	++++

- 30 0 resistant;
+ relatively sensitive;
++ moderately sensitive;
+++ very sensitive;
++++ extremely sensitive.

35

In view of the data in the above Table A it is stated that diseases, caused by the microorganisms in Table A can be cured by pharmaceutical preparations based on origanum oil as active component.

40

In view of the above, the pharmaceutical compositions are particularly used for prevention and treatment of gastro-intestinal infections in humans and particularly in animals, which are caused by the bacteria, fungi etc.; see in this respect the enumeration below:

45

Figs: E.coli, Salmonella spp., swine dysentery, Pasteurella spp.

Poultry: (chickens, ducks, turkies): Eimeria spp. (coccidiosis), Salmonella spp., Pasteurella spp.

Rabbits: Eimeria spp. (coccidiosis), Salmonella spp.

Cows: calves-E.coli, Pasteurella spp., Salmonella spp.

5 Lambs: Salmonella spp., Pasteurella spp., Clostridium perfringens, E.coli.

Young goats: (kids): Salmonella spp., Pasteurella spp., Clostridium spp., E.coli.

10 Further to the diseases mentioned above, the pharmaceutical composition according to the invention can be applied for the treatment of:

- toxoplasmosis caused by *Toxoplasma gondii* by animals and humans;
- internal parasites of dogs like *Toxocara canis*, *Echinococcus*
- 15 *granulosis* etc.;
- sarcocystoses by dogs, cattle, poultry and humans;
- ascaridosis by pigs and poultry, caused by *Ascaris suum* and *Ascaris galii*;
- oxyurosis equi by horses and heteracidosis by poultry;
- 20 - teniosis by humans and cysticerocis by pigs;
- ancylostoma duodenalis and oxyurosis by humans;
- rheumatic diseases like arthritis, spondylitis, dyscilioathie, and injuring like distorsio, subluxatio etc.;
- fungi and insects on plants in the agricultural sector;
- 25 - demodicosis by dogs;
- diarrhea, caused by *Escherichia coli* (colibacillosis), *Salmonella* spp. (salmonellosis), *Pasteurella* spp. (pasteurellosis), *Streptococcus* spp. (streptococcosis), *Vibrio coli* (vibriosis). *Treponema hyodesynerie* (dysentery-bloody diarrhea), and other kinds of
- 30 diarrhea by human and animals;
- parasitosis caused by *Cryptosporidia* spp., *Ascaridia* spp., *Toxocara* spp., *Toxoplasma* spp., *Atoxoplasmosa*;
- diseases caused by *Candida albicans*, *Aspergillus* spp., *Cryptococcus neoformans*, *Mucor* spp., *Fusarium* spp., by humans and animals; and
- 35 - cestodosis by birds and poultry.

The compositions according to the invention, in particular in the form of a powder comprising 5% of *origanum vulgare* oil, can also

be used for the conservation of food for humans and for the conservation of feed for animals and do prolong the storage life of such products.

5 A process for extracting the etheric oils from the above-mentioned plants, in particular *Origanum vulgare*, *Thymus vulgare* and *Mentha piperita* is carried out by distillation with the help of water vapour (steam).

10 Firstly, the leaves and blossoms of the plants, which must be dry, are placed in a distiller. In case of human application of the oils obtained, the distillation of the oil from every type of plants is done separately, which means that different types of plants must not be mixed together in the process of distillation.

15 The distiller should have two output tubes: one for the oil and one for the water vapour (steam). The dish for the water is placed under the dry parts of the plant (the leaves and blossoms) and heated up to 100°C, preferably under a pressure of about 20 bar as an increased pressure will reduce the distillation time. The water vapour passes through the dry parts of the plant, thereby creating oil drops. The drops of water vapour are lighter than the
20 oil drops, hence flow out the output tube at the bottom of the extractor. The drops of oil flow out the output tube for the oil and into the dish intended for the oil. This process is carried out for 3 hours. The yield is 3-6 kg of oil from 100 kg of dry plants. In general the extracted oil contains a certain percentage of tymol and
25 carvacrol: approx. 3% of tymol and 60-70% of carvacrol.

After the above-described distillation, the residue of the leaves and blossoms is used to extract tannin, which can be added to, in particular, veterinary pharmaceutical compositions.

30 More in particular the procedure for obtaining etheric oils from *Origanum vulgare* plants consists of four phases:

Phase 1: Selection

35 On the basis of the existing types of *Origanum vulgare* plants it has been possible to obtain seeds of *Origanum vulgare* plants having about 91% active material: 86-88% carvacrol and 3-5% thymol. The remnant 8-10% does comprise the following components:

linalol, barneol, cimen and some other less important components.

Phase 2: Production of the plants

5 The seeds obtained in the way according to phase 1 are planted in fine loose soil, preferably in a sub-tropical climate. During this process all agro-technical measures are applied, like watering and artificial fertilizing.

10 From the already grown plants, only their leaves and blossoms should be used. The reaping should be undertaken while the plants are in blossom early in the morning or late in the evening hours.

Phase 3: Drying of the leaves and blossoms

15 The drying process is performed in special rooms, i.e. drying houses. The already harvested leaves and blossoms should not be exposed to direct sunlight since any exposure to sunlight significantly decreases the percentage of active material.

20 The leaves and blossoms are arranged in layers of 20-25 cm thick. During the first three days, these layers should be turned up-side-down four times a day, either manually or mechanically, so that this drying process is proceeded in an uniform way.

These drying houses are constructed in such a way, that the air is able to circulate freely all the time.

The drying process lasts about 7-8 days.

Phase 4: Production of the oil

25 From the dried leaves and blossoms of the plants, a distillation of the oil is carried out on the basis of a classic steam distillation. Out of 100 kilos of dried leaves and blossoms 5-7 kilos of oil are obtained.

30 After the distillation step according to which the oil has been obtained, the following step is carried out:

35 - the oil is heated at 187°C, during which process, again performed in the distillator, the substances, which are of no importance are evaporated. The remnants are the important substances: carvacrol 86-88%; thymol 3-5% and in minor quantities: pinene, barneol, linalol etc.

After this redistillation process, the oil is left to cool to

room temperature and is then packed in hermetically closed vessels made of aluminum or dark glass.

The invention will be elucidated by the following series of examples, i.e. (A) examples concerning the compositions and preparation of human pharmaceutical medicaments, (B) examples concerning the compositions and preparation of veterinary pharmaceutical medicaments, (C) examples concerning the activity of pharmaceutical medicaments according to the invention and (D) examples concerning the safety of pharmaceutical medicaments according to the invention. The percentage is expressed as percentage by weight unless otherwise indicated.

A) COMPOSITION AND PREPARATION OF HUMAN PHARMACEUTICAL MEDICAMENTS.

Example 1

Medicaments for the treatment of colibacillosis, salmonellosis, pasteurellosis, vibriosis and cholera; the diseases are caused by *Escherichia coli*, *Salmonella typhimurium*, *Vibrio fetus* and *Pasteurella multocida*.

1.1 Procedure for making capsules.

The integral parts of the substances from which the medicament is prepared are:

- lactose	90-92%
- Origanum vulgare oil	4-6 %
- Thymus vulgare oil	2-4 %
- Mentha piperita oil	0.5-1.5%

Firstly, about 30% of the lactose and the total amount of oils are put in a vacuum mixer. The mixture is mixed for five minutes at a speed of 200 rotations per minute. Then the rest of the lactose is added and everything is mixed together for another 10 minutes at the above-mentioned speed. Finally, the powder is packed

into capsules.

1.2 Procedure for making a syrup.

5 The integral parts of the substances from which the medicament is prepared are:

	- honey as the basic element	92-94%
	- Origanum vulgare oil	2-4 %
10	- Thymus vulgaris oil	1-3 %
	- Mentha piperita oil	0,5-1,5%

15 30% of the overall amount of honey in a liquid form is placed in a vacuum mixer and the whole amount of oils is added. The mixture is mixed for 15 minutes at a speed of 200 rotations per minute. Then the rest of the honey is added and mixed for another 15 minutes at the above-mentioned speed. The resulting product is a syrup in liquid form, which can be packed as soon as it is cooled down.

20 Example 2

Medicaments for the treatment of dermatomycosis: dermatomycosis may be caused by *Trichophyton sp.* and *Microspora sp.*

25 2.1 Process for obtaining a tincture.

 The integral parts of the substances used to prepare the medicament are:

	- polyethylene glycol	72-74%
30	- laurel	19-21%
	- Origanum vulgare oil	3-5 %
	- Thymus vulgaris oil	1-3 %
	- Mentha piperita oil	0.5-1.5%

35 Approximately 30% of the overall amount of polyethylene glycol is heated in a vacuum mixer up to 55°C. The total quantity of oils is added and mixed at a speed of 200 rotations per minute. At

the end the rest of the polyethylene glycol and the laurel are added and this is mixed for five more minutes at the above-mentioned speed. After it is cooled down, the product is ready to be packed.

5 2.2 Procedure for making an ointment.

The integral parts of the substances used to make the ointment are:

	- vaselin album	67-69%
10	- parafinum liquidum	24-26%
	- Origanum vulgare oil	3-5 %
	- Thymus vulgare oil	1-3 %
	- Mentha piperita oil	0.5-1.5%

15 30% of the vaselin album is melted in a vacuum mixer at a temperature of 45°C. The oils are added and everything is mixed together for 10 minutes at a speed of 250 rotations per minute. Then, the rest of the vaselin and the parafinum liquidum are added. Everything is mixed for another 10 minutes at the above-mentioned
20 temperature and packed after it is cooled down.

Example 3

25 Medicaments for the treatment of colpitis (for women):
colpitis may be caused by *Trichomonos genetalis*.

The substances used to prepare this medicament are:

	- starch dextrose	51-53%
	- hygroscopic carrier	19-21%
30	- kolloid	19-21%
	- Origanum vulgare oil	2-4 %
	- Thymus vulgare oil	2-4 %
	- Klamath weed oil	1-3 %

35 The process is as follows: the starch dextrose and the neutral hygroscopic carrier are placed in a vacuum mixer. The prescribed quantities of oils are added to this mixture and every-

thing is blended at a speed of 200 rotations per minute. At the end, the kolloid is added, everything is mixed one more, and packed.

Example 4

5

Product against lice and other types of skin insects: e.g. mosquitos and flies.

The substances used to obtain the product are:

10

- | | |
|------------------------|--------|
| - Laurel | 91-93% |
| - Origanum vulgare oil | 4-6 % |
| - Thymus vulgare oil | 2-4 % |

15

All the parts listed above are put in a vacuum mixer. They are mixed together at a speed of 200 rotations per minute, for 10 minutes, after which the mixture is packed. The advantage of this product over the chemical ones made on the basis of lindane is that the medicaments according to the invention are completely non-toxic for humans and animals.

20

Example 5

25

Product for the prevention of foot perspiration and of the presence of fungus on feet: *Trychophyton sp.* and *Microspora sp.*

The substances that are used in the procedure for preparing these medicaments are:

30

- | | |
|------------------------|--------|
| - calcium carbonate | 91-93% |
| - Origanum vulgare oil | 4-6 % |
| - Thymus vulgare oil | 2-4 % |

35

30% of the calcium carbonate and the total amount of the oils are put in a vacuum mixer. The mixture is mixed for 10 minutes at a speed of 200 rotations per minute and subsequently the rest of the calcium carbonate is added. The mixing is continued until a powder is obtained.

Example 6

Product for the extermination of insects and other pests:
e.g. mosquitos and flies.

5

The substances that are used in the process of preparing this product are:

- calcium carbonate	91-93%
- Origanum vulgare oil	4-6 %
10 - Thymus vulgaris oil	2-4 %

30% of the calcium carbonate together with the entire amount of oil is put in a vacuum mixer. The mixture is blended for 10 minutes at a speed of 200 rotations per minute. Subsequently, the rest of the calcium carbonate is added and the mixing is continued until a fine powder is obtained.

15

Example 7

Medicament for the treatment of dermatitis, acne and other inflammations of the skin on the face.

20

The subsequences from which the medicament are prepared are:

- laurel	72-74%
25 - ethanol	19-21%
- Origanum vulgare oil	3-5 %
- Thymus vulgaris oil	2-4 %

Some 30% of the laurel together with the whole amount of oils is put in the vacuum mixer. It is mixed for 10 minutes at a speed of 200 rotations per minute. Subsequently, the rest of the laurel and the ethanol are added and the product is mixed and packed in dark glass bottles.

30

Example 8Medicament for wounds

5 The substances used in the process for preparing the medicament are:

- neutral medical powder 94-96%
- Origanum vulgare oil 2-4 %
- Thymus vulgare oil 1-3 %

10

30% of the neutral medical powder and the total amount of oils are put in the vacuum mixer and mixed together for 10 minutes at a speed of 200 rotations per minute. Subsequently, the rest of the neutral medical powder is added and mixed. The product is packed

15 in small bags or aluminium tubes under pressure.

B) COMPOSITIONS AND PREPARATION OF VETERINARY PHARMACEUTICAL MEDICAMENTS.

20

Example 9

Medicaments for the treatment of colibacillosis and gastroenteric diseases in animals; colibacillosis may be caused by *Escherichia coli* and other species: *Salmonella*, *Pasteurella*, *Vibrio*, *Treponema*, *Hiodysenterie* and *Cryptosporidiosae sp.*

25

9.1 Procedure for making a powder.

The substances which are used in the procedure for making a powder for the treatment of colibacillosis are:

30

- calcium carbonate 91-93%
- Origanum vulgare oil 3-5 %
- Thymus vulgare oil 1-3 %
- Mentha piperita oil 0.5-1.5%
- 35 - tannin 0.5-1.5%

30% of the total quantity of calcium carbonate is put in a turbo vacuum mixer and the entire amount of etheric oils is gradually added. The total product is mixed together at a speed of 250 rotations per minute for 10 minutes. The etheric oils are mixed together directly before being poured in the mixer. After the mixing time of 10 minutes, the rest of the calcium carbonate is added and mixed at the above-mentioned speed for another 5 minutes. The powder is then ready to be packed.

9.2 Procedure for making an emulsion.

In one case the substances which are used in the procedure for preparing the product are:

- polyethylene glycol	89.5-91.5%
- Origanum vulgare oil	3-5 %
- Thymus vulgaris oil	1-3 %
- Mentha piperita oil	0.5-1.5%
- tannin	0.5-1.5%
- glycerol monostearate	1-2 %

and in the second case these substances are:

- laurel oil	91-93%
- Origanum vulgare oil	3-5 %
- Thymus vulgaris oil	1-3 %
- Mentha piperita oil	0.5-1.5%
- tannin	0.5-1.5%

The procedure is in both cases the same. Firstly, 30% of the basic substance is placed in a turbo vacuum mixer (in the first case, the polyethylene glycol, and in the second case the laurel oil) and the mixture of oils is added. Everything is mixed together for a period of 5 minutes at a speed of 200 rotations per minute. After this is done, the rest of the basic substance is added. In the first case the glycerol monostearate is added as well. It is mixed for another 10 minutes with the same intensity. At the end it is packed in dark glass bottles.

9.3 Procedure for the production of capsules.

The substances which are used in the procedure for preparing the product are:

5	- lactose	91-93%
	- Origanum vulgare oil	3-5 %
	- Thymus vulgare oil	1-3 %
	- Mentha piperita oil	0.5-1.5%
	- tannin	0.5-1.5%

10

Firstly, the three types of oils are mixed in the given percentage. The mixture is then blended together in a mixer with 30% of the lactose at a speed of 200 rotations per minute for a period of 10 minutes. The rest of the lactose is added and mixed again. The mixture is then put in capsules.

15

9.4 Procedure for making a paste.

The elements which are used in the procedure are:

20	- vaselinum album	69-71%
	- Origanum vulgare oil	3-5 %
	- Thymus vulgare oil	1-3 %
	- Mentha piperita oil	0.5-1.5%
	- tannin	0.5-1.5%
25	- parafinum liquidum	21-23%

30

The procedure for making the paste goes as follows: the vaselinum album is placed in the mixer together with 20% of the total contents and heated up to a temperature of 40°C. The heated mass is then added to the mixture of above-mentioned quantities of oil and the product is mixed together for 5 minutes at a speed of 100 rotations per minute. At the end the parafinum liquidum is added and the product is packed.

Example 10

Product for the treatment and prevention of coccidiosis in livestock: coccidiosis may be caused by *Eimeria tenella*, *Eimeria phasani*, *Eimeria mecatrix*, *Eimeria duodenalis*, *Eimeria acervulina*,
5 *Eimeria colchici*, *Eimeria maxima*, *Eimeria praecox*, *Eimeria brunetti*,
Eimeria Hagani, *Eimeria mitis*, *Eimeria mivoti*.

The substances which are used in the preparation of the
10 product are:

- calcium carbonate	92-94%
- Origanum vulgare oil	3-5 %
- Thymus vulgare oil	1-3 %
- Mentha piperita oil	0.5-1.5%

15

20% of the calcium carbonate is put in a turbo vacuum mixer and the total amount of oils is added after being mixed beforehand. The product is blended together for 10 minutes at 200 rotations per minute. Then the rest of the calcium carbonate is added and mixed
20 again for another 10 minutes. Finally the product is packed.

Example 11

Product for the treatment of mastitis: mastitis may be caused
25 by *Streptococcus uberis*, *Staphylococcus aureus*, *Escherichia coli*,
Cryptococcus neoformans, *Candida albicans*, *Spheroforus necroforus*,
Streptococcus agalactie.

The substances which are used in the procedure for the
30 preparation of the product are:

- vaselinum album	92-94%
- parafinum liquidum	22-24%
- Origanum vulgare oil	3-5%
- Mentha piperita oil	0.5-1.5%

35

20% of the vaselinum album is put in a mixer that is previously heated at 45°C. After the substance is melted the mixture

of the given quantities of oils is added and mixed for 5 minutes at a speed of 200 rotations per minute. The rest of the vaselinum album and all of the parafinum liquidum are added as the product cools down. Then, the product is packed in appropriate syringes.

5

Example 12

Product having anti-dermatitis properties: dermatitis can be caused by *Trychophyton sp.* and *Microspora sp.*

10

The substances used in the procedure for preparing the product are:

- vaselinum album	69-71%
- parafinum liquidum	21-23%
15 - Origanum vulgare oil	3-5 %
- Thymus vulgaris oil	2-4 %
- Mentha piperita oil	0.5-1.5%

20

20% of the vaselinum album is put in a mixer which is previously heated at 45°C. The oils are added and the product is mixed for 10 minutes at a speed of 50 rotations per minute. Then the rest of the vaselinum album and the parafinum liquidum are added. Finally the mass is cooled down and packed in appropriate tubes.

25

Example 13

Products for the treatment of animal wounds.

30

The substances used in the procedure for preparing the product are:

- medical powder	92-94%
- Origanum vulgare oil	4-6 %
- Thymus vulgaris oil	0.5-1.5%
- Mentha piperita oil	0.5-1.5%

35

20% of the medical powder is put in a vacuum mixer and mixed together with the oils which are mixed beforehand. The mixture is

blended together for 10 minutes at a speed of 200 rotations per minute. Then the rest of the medical powder is added and mixed another 5 minutes at a speed of 150 rotations per minute. Finally the powder is packed in bags or bottles under pressure.

5

C) EXAMPLES CONCERNING THE ACTIVITY OF VETERINARY PHARMACEUTICAL MEDICAMENTS ACCORDING TO THE INVENTION.

Example 14

10

Introduction

Coccidiosis belongs to the most common acute diseases of the modern poultry upbringing. The disease is caused by monoxenous intercellular parasites from *Eimeria* species, from which pathogenicity depends the state of the disease and mortality level. Aiming for prevention and eradication of the coccidia today many chemotherapeutics are being used, but there appears to be a problem with the resistance of these parasites to them, especially if used inadequate and without changes. For this reason, it has been started to achieve immune protection of the poultry (vaccines) by means of a preparation according to the invention composed of 5% by weight of *Origanum vulgare* oil and 95% by weight of CaCO_3 and indicated below as "preparation A".

15

20

25

Materials and methods of work.

The tests have been done on 75 chickens of the "Hybro" species. The chickens were grown on one mini-farm, with floor system and fed by standard concentrate "ad libidum". At the beginning of the test they have been separated in three groups of 25 animals each.

30

Group A: In 25 chickens one day old, preparation A has been added to the food as a prevention dose, which is 0.25 gr/kg of food within 7 days. After 7th day, there has been found an infection by oocysts of *E.Tenella* and *E.Acervulina*. After the infection there has been an observation of the chickens up to 28 days with regular examination of excrement. After 28th day, the chickens are

35

sacrificed and examined for its parasitology section, together with the examination of the excrement.

5 Group B: Within this group of chickens, 25 chickens were
given concentrate without coccistatics and test-preparation A. After
7th day the infection by oocysts *E.Tenella* and *E.Acervulina* has
appeared. The same day preparation A has been mixed with the food of
the animals in a concentration of 0.5 gr/kg of food. The chickens
have been fed by food mixed this way for seven days, and after this,
10 performed the observation followed by regular parasitology exami-
nation started at the moment of the detection of the infection. After
28th day, the chickens are sacrificed and examined for its para-
sitology section, together with the examination of the excrement.

15 Group C: In this group counting 25 chickens, animals were
fed 7 days with pure food, and after 7th day there has appeared an
oocyst of *E.Tenella* and *E.Acervulina* infection. After clinically
manifested disease (7th day after infection) their food with mixed
concentrate and preparation A has started, in a concentration of 0.5
20 gr/kg of food. The treatment lasted for 7 days while regular para-
sitology examination have been performed, lasting until 28 days old
chickens, when sacrificed, examined for its parasitology section,
together with the examination of the excrement.

25 The infection of the poultry has been obtained by tetrenic
isolates of oocysts of *E.Tenella* and *E.Acervulina*, which after
standard application and examination of the sporulation have been
given to each individual chicken in doses of 1×10^5 oocysts. The
examination have been performed by standard parasitology methods
30 given by Johnson J. and Reid W.M., 1970, Anticoccidial drugs: lesion
scorion technique in battery and floar pen experiments with
chickens, Exp.Parasitol. 28, 30-36. The examination have been done
first day after moving in the chickens, and after their infection in
two days intervals during complete test.

35

The results of tests and discussion.

By examination done the first day after moving in of the

poultry, there has not been found a parasite infection in the animals. After the infection the examination have been performed in two days intervals, in all three experiment groups. In groups A and B while experimented, there have not been noticed the coccidia in excrement. In group C the sixth day after infection the clinical symptoms of coccidiosis have been noticed (diarrhea, characteristic behaviour ...) as well as presence of oocysts of coccidia in the excrement. Second day after treatment, the diarrhea has stopped but in the excrement there could still be found the oocysts of coccidia. On the fourth day the number of oocysts has significantly lowered and during next controls it has dropped to a minimum. The clinical picture of the disease has stopped after the fifth day of the treatment. There have not been any chicken dead. After sacrifice of the chickens the parasitology section, together with the examination of the excrement have been performed by method of Johnson and Reid (1970), loc.cit. In groups A and B they have not been noticed while in group C they were not significantly important (level +1 according to this scale, never more than this).

Based on preliminary examination it can be concluded that the application of the preparation A can be used for coccidiosis of the poultry and have been efficient in preventive and therapy effect. Having in mind that the preparation contains 5% of ethereal oil of *Origanum vulgare* flower and leaf, which has healing effect on the intestinal tract and probably is this fact the reason for the absence of changes in digestive tract of infected poultry clinically found before the application of the therapy. Within this group, the quick recovery has been noticed and they have developed normally. It has been noticed that poultry has normally taken the medicated food and that the strong smell of oregano has been absorbed in the food normally and therefore kept unnoticed. The powder is a better form for homogenization in concentration-form for the poultry. While the experiment was lasting, it has been taken care of the fact that poultry got all food ad libidum, and that the micro-climate in the object moved between optimal limits for this kind of production and that optimal space was provided for the animals.

Conclusion:

Based on performed experiment using preparation A for use of the prevention and eradication of coccidiosis in chickens upbringing we can conclude the following:

- 5 - The preparation in the concentration of 0,25 gr/kg of food can be successfully used in prevention of this disease. The preparation should be used by adding it to the food within 7 days;
- 10 - The preparation in the concentration of 0,50 gr/kg of food can be successfully used during the beginning and clinically manifested form of coccidiosis. Therapy should be applied for 7 days;
- 15 - The preparation mixes easily with the food. The smell of the preparation is strong, specific-oregano, but in the food it cannot be tasted. Chickens eat normally food with mixed preparation in it;
- In treated chickens there were no side effects noticed as a consequence of the application of this preparation;
- 20 - The preparation can be applied both for preventive or therapeutical use, and also for other diseases of poultry.

Example 15Introduction

25 As brought up in example 14, coccidiosis belongs to the most common parasitic diseases of poultry, for instance pheasants in intensive upbringing. The most common clinically manifested disease appears in pheasants aged 4-6 weeks, causing significant losses to this production. The eradication of the coccidiosis-prevention and
30 therapy is analogue to the poultry production with the application of identical therapeutics. Problem of the resistance to it is present in this case as well. For these reasons the testing of the preventive and therapeutical effect of the preparation A (defined in example 14) has been done and obtained results have shown significant
35 efficiency of this preparation used in this test.

Materials and methods of work.

The tests have been done on pheasants 3-6 weeks old, bearing in mind that coccidiosis in clinically manifested form appears in pheasants 4-6 weeks old. Based on dynamics of the production in the pheasant farm, every group of the birds counts approximately 2000 animals. The experiment has been performed on three groups.

Group A: On pheasants three weeks old, after performed parasitologic examination, in which no infection of cocci was found, preparation A has been added to the food. For prevention purposes, the preparation has been given in a concentration of 0,25 gr/kg of foods seven days in a row.

Group B: Within this group of pheasants, 24 days old, in obduction has been found the beginning stadium of the cocci infection. The estimation of the infection degree is being observed through the number of cocci and pathological changes in intestines. Determination of the causer-species is done based on their morphological characteristics. After diagnosis the therapy doses of preparation A has been given in a concentration of 0.5 gr/kg of foods seven days in a row.

Group C: In this group the spring pheasants 4 weeks old, have clearly shown clinical symptoms of the disease. Characteristic behaviour of the birds and diarrhea were obvious in this group. Noticed there were hemoragical enteritis, which mycosis corks in cecum. The death of the pheasants was within the limits of 50-60 birds daily. The therapy of preparation A has been applied in concentration of 0,5 gr/kg of food.

Diagnosis of coccidiosis has been made by taking samples of excrement and its examination by standard parasitology methods. The smear of the mucous membrane has been done from the changed areas on intestines of the diseased pheasants. The estimation of extensivity and intensity of the infection has been done by counting oocysts of cocci, and based on degree of pathological changes. Determination is obtained based on morphological characteristics of the parasites by

means of the Norton method (1981).

THE RESULTS OF TESTS AND DISCUSSION

5 **Group A:** Coccidiostatic effect of the preparation A has been completely successful. During the observance of the animals for three weeks of this group of pheasants (ending 6th week) there were no cases of the presence of cocci. In obduction there were no parasite elements found (oocysts of cocci). Pheasants have normally developed, and the degree of mortality was below technological range
10 anticipated for this production (in average 1,1%).

Group B: Within this group of pheasants the beginning infection has been diagnosed, caused by *E.Duodenalis* and *E.Colchici*.
15 The degree of the mortality was within technological limits, but the indication symptoms of the infection have been noticed. After 7-days therapy the symptoms have completely disappeared and in obduction of died and sacrificed animals there were no pathological changes in intestines and coccum, characteristic for coccidiosis. The
20 examinations of the smear of mucous membrane have shown that the disease has not developed.

Group C: This group had present coccidiosis in clinical range followed by mortality of 2,5%. Infection has been caused by
25 *E.Duodenalis* and *E.Colchici*. Therapy has been applied for 7 days. During the first three days the mortality has been significantly decreased, while after finished therapy coccidiosis has been eradicated completely. This has been approved by obduction and parasitology examination of the sacrificed and died pheasants.

30
 In both groups (B and C) where the infection has been noticed, after therapy there has been an important and significant approval in conditional and healthy state of the birds. Following the development of these birds for next weeks, it has been noticed that
35 vitality and development is within optimal range for this species. Estimation and following of the mortality of the birds has been made difficult by getting the weather conditions worse (severe drop in

temperature, heavy rains followed by wind), so that in second week of the observations a slight increase of mortality has appeared, but based on section of died animals (72 from B group, 61 from C group, and 60 from A group) and parasitology examination of died animals and group excrement from experimental groups there was no coccidiosis found.

Conclusion:

Based on performed experiments using preparation A for use of the prevention and eradication of coccidiosis in pheasant game birds in intensive upbringing we can conclude the following:

- The preparation in the concentration of 0,25 gr/kg of food can be successfully used in prevention of this disease. The preparation should be used by adding it to the food within 7 days;
- The preparation in the concentration of 0,50 gr/kg of food can be successfully used during the beginning and clinically manifested form of coccidiosis. Therapy should be applied for 7 days;
- The preparation mixes easily with the food. The smell of the preparation is strong, specific-oregano, but in the food it cannot be tasted. Pheasants eat normally food with mixed preparation in it;
- In treated pheasants there were no side effects noticed as a consequence of the application of this preparation;
- The preparation can be applied both for preventive or therapeutical use, for the diseases of bacteridical or mycological ethiology of game birds. Based on shown coccidiostatic effect it may be applied for this use, like with application of other coccidiostatics (from third to eight week of upbringing).

D) EXAMPLES CONCERNING THE SAVETY OF VETERINARY PHARMACEUTICAL MEDICAMENTS ACCORDING TO THE INVENTION.

Example 16

1. Introduction

In this example a study is carried out to get more

information about the safety of pharmaceutical compositions comprising etheric oil of *origanum vulgare* (oregano oil) in broiler chicks. For this purpose two dietary levels were included in the trial: the normal recommended dose level of 250 ppm oregano oil and
5 a dose level 10 times the recommended level (2,500 ppm of oregano oil). The latter dose level is generally used for testing the safety of products in order to apply for EU-registration referring to Council directive (COM C93 113) and Council decision (COM (93) 114). As a reference product, a commercially used antibiotic
10 (virginiamycin; 20 ppm) was included in the trial. Birds were housed in battery cages for a period of 34 days. The criteria studied were weight gain, feed intake, feed conversion efficiency, water intake and general state of health.

15 2. Experimental procedure

2.1 Experimental groups

The following four experimental groups were involved in the
20 trial:

Group	Diet
I	Basal diet (control diet without antibiotics)
II	Basal diet + 250 ppm oregano oil
III	Basal diet + 2,500 ppm oregano oil
25 IV	Basal diet + 20 ppm virginiamycin

Each experimental group consisted of 90 chicks, six replicate cages with each 15 female birds.

30 2.2 Animals

A normal broiler cross ("Ross") was used. At the time of arrival at the institute, 460 one day old female birds were divided at random among 24 cages. During the pre-test period of 5 days all
35 birds were fed a standard diet. At an age of 5 days 360 birds were

selected and divided at random among the experimental groups according to body weight. The allocation was done in such a way as to obtain within each group two cages with 15 birds of an average body weight of 114 g, two with an average body weight of 107 g, and two with an average body weight of 102 g. After allocation the chickens were fed the experimental diets for 29 days (age period 5-34 days).

2.3 Variations

The birds were vaccinated for Newcastle disease (according to the spray method) at an age of one and fourteen days.

2.4 Housing

The birds were housed in battery cages, situated in an artificially heated, ventilated and lighted broiler house. The broiler house involved 72 cages. The floor space of each cage was 0.98 square metres with wire floors. Each cage was provided with an automatic water supplier and a feed trough. Per cage, 15 birds were housed. The broiler house was illuminated 24 hours a day. During the experimental period, the light intensity was gradually reduced. The temperature in the broiler unit was gradually reduced from 28°C during the first week to 23°C during the last days of the experiment. The humidity in the broiler unit was approximately 55% during the experimental period.

2.5 Diets

For the experiment one batch of feedstuffs were used. The composition of the basic diet is presented in Table B. No coccidiostat was added to the diets.

The experimental diets were prepared at a feed mixing plant. The basal diet of the experimental groups was mixed as one batch for all groups. The experimental diets were then prepared by splitting up this batch into four batches to which the required amount of feed additives were added, and mixed. Next the diets were pelleted (2.5

mm) without the addition of steam. The pelleting temperature, measured after the pellets left the press, was approximately 54°C. The basal diet was analysed for the content of crude protein, Ca and P.

5 The diets were fed ad libitum. Water was also available ad libitum via an automatic device.

TABLE B
Composition of the basal diet (in %)

	Ingredient		
5	Wheat	35.00	
	Corn	10.00	
	Soya oil	3.10	
	Animal fat	3.00	
	Tapioca	3.94	
10	Peas	10.00	
	Soyabean meal (47.6% CP)	15.00	
	Soyabean heattreated	5.00	
	Sunflower meal	5.00	
	Meat meal tankage (58% CP)	5.00	
15	Feathermeal (hydr. 82% CP)	1.50	
	Vitamin-mineral mix *	1.00	
	Limestone	0.88	
	Monocalciumphosphate	0.92	
	Salt	0.26	
20	L-lysine HCl	0.20	
	Dl-methionine	0.20	
	Crude protein	22.3 (21.9)	
	Dig. crude protein	18.3	
	ME broilers (kcal/kg)	2900	
25	ME roosters (kcal/kg)	3140	
	Crude fat	9.4	
	Crude fibre	3.6	
	Ash	5.8	
	Calcium	0.86 (0.85)	
30	Phosphorus	0.71 (0.73)	
	Available P	0.45	
	Sodium	0.16	
	Potassium	0.85	
	Chloride	0.28	
35	Magnesium	0.16	
	Linoleic acid	3.0	
	Amino acids:	Total AFD **	
40	Lysine	1.28	1.09
	Methionine	0.54	0.48
	Meth. + Cyst.	0.94	0.79
	Threonine	0.82	0.67
	Tryptophan	0.24	0.20
	Isoleucine	0.90	0.76
45	Leucine	1.65	1.40
	Phenylalanine	1.03	0.88
	Tyrosine	0.70	0.58
	Valine	1.06	0.87
	Arginine	1.48	1.28
50	Histidine	0.51	0.43

- 5 * Supplied per kg diet: riboflavin, 4 mg; niacinamide, 40 mg; d-pantothenic acid, 12 mg; choline-chloride, 500 mg; cobalamin, 15 µg; D1-α-tocopheryl acetate, 15 mg; menadione 5 mg; retinyl-acetate, 3.44 mg; cholecalciferol, 50 µg; biotin, 0.1 mg; folic acid, 0.75 mg; FeSO₄.7H₂O, 300 mg; MnO₂, 100 mg; CuSO₄.5H₂O, 100 mg; ZnSO₄.H₂O, 150 mg; Na₂SeO₃, 0.15 mg; KI, 5 mg; CoSO₄.7H₂O, 1 mg; antioxidant (ethoxyquin), 100 mg; and 20 mg virginiamycin in phase 2.
- 10 ** Apparent faecal digestible amino acids.
() Analysed contents

3. Criteria studied

- 15 - Individual body weight after an experimental period of 14 and 29 days.
- Feed consumption for each replicate of 15 birds, at each time of weighing.
- Feed conversion efficiency, calculated as kg feed consumed/kg weight gain, at each time of weighing. The data for feed consumption and conversion efficiency were corrected for the estimated amount of feed consumed by birds which died during the experimental period.
- 20
- Water consumption and feed intake for each replicate of 15 birds, during one period of four days (24-28 days of age).
- 25
- Mortality rate, and general state of health.

4. Statistical analysys

- 30 The results for weight gain, feed conversion efficiency, feed intake and water consumption were analysed statistically. Results for weight gain, daily feed intake, and feed conversion efficiency are corrected for sex errors and 'outliers'. Differences among experimental groups were tested for significance by analysis of variance followed by the Least Significance Difference test (Snedecor and Cochran, 1980). The computer program SPSS/PC+ V5.0 (Norusis, 1992) was used to calculate the analysis of variance. All statements of significance are based on a probability of $P \leq 0.05$.
- 35

5. Conclusion

The results for weight gain, daily feed intake, and feed conversion efficiency at 14 and 29 days experimental period are presented in Tables C and D. Supplementation of either 250 or 2,500 ppm of oregano oil to the diet had hardly any effect on weight gain and feed conversion efficiency after 14 and 29 days experimental period. Virginiamycin when added to the diet tended to improve weight gain and feed conversion efficiency after 14 days experimental period, whereas hardly any effect on broiler performance was obtained after 29 days experimental period. The results for water intake and water/feed ratio are presented in Table E. Inclusion of either 250 and 2,500 ppm of oregano oil, or 20 ppm virginiamycin in the diet had hardly any effect of daily water intake and water/feed ratio.

Mortality rate was low, 1.4% (= 5 animals), with no appreciable differences among the treatment groups. In addition, no abnormalities regarding the health status were observed during the trial. The low mortality rate obtained during the present trial indicates that the animals were in good health condition. This good health condition of the birds in the present study may explain the fact that hardly any effect of virginiamycin on broiler performance was observed, whereas normally an improvement in feed conversion efficiency is observed. Based on the results of the present study it can be concluded that oregano oil has no negative or detrimental effect on performance of healthy broiler chicks when supplemented 10 times the recommended level.

TABLE C

Results for body weight gain, daily feed intake, and feed conversion efficiency of broiler chicks after 14 days experimental period (5-19 days of age).

Group	Addition of	Weight gain		Feed intake		Feed gain	
		(g)	%	(g/d)	%	ratio	%
I	-	585	100	60.6	100	1.450	100
II	250 ppm Origanum oil	577	98.6	59.4	98.0	1.441	99.4
III	2.500 ppm Origanum oil	582	99.5	60.3	99.6	1.452	100.1
IV	20 ppm virginiamycin	592	101.1	60.5	99.8	1.431	98.7
LSD (P=0.05)		14		1.0		0.021	

TABLE D

Results for body weight gain, daily feed intake, and feed conversion efficiency of broiler chicks after 29 days experimental period (5-34 days of age).

Group	Addition of	Weight gain		Feed intake		Feed gain	
		(g)	%	(g/d)	%	ratio	%
I	-	1590	100	93.7	100	1.710	100
II	250 ppm Origanum oil	1571	98.8	92.2	98.3	1.702	99.5
III	2.500 ppm Origanum oil	1593	100.2	94.0	100.3	1.711	100.1
IV	20 ppm virginiamycin	1606	100.3	93.4	99.6	1.697	99.3
LSD (P=0.05)		38		1.9		0.024	

TABLE E

Results for water consumption and water feed ratio of broiler chicks during one period of four days (24-28 days of age).

Group	Addition of	Daily water intake		Water/feed ratio	
		(g/d)	%	ratio	%
I	-	291	100	2.06	100
II	250 ppm Origanum oil	295	101.3	2.07	100.7
III	2,500 ppm Origanum oil	295	100.3	2.09	101.4
IV	20 ppm virginiamycin	290	99.6	2.08	101.2
LSD (P=0.05)		13.2		0.07	

CLAIMS

1. Pharmaceutical composition, characterized in that the active agent is at least an oil, extracted from any of the plants, selected from the group consisting of *Origanum vulgare*, *Thymus vulgare*, *Mentha piperita*, *Thymus serpyllum*, *Saturea hortensis*, *Saturea montana*, *Saturea subrepens*, *Carum carvi*, *Thymus zosterifolius*, *Ocimum basilicum*, *Morinda officinalis*, *Mosla japonica* and *Salvia officinalis*.

2. Pharmaceutical composition according to claim 1, characterized in that the active agent is at least an oil, extracted from any of the plants, selected from the group consisting of *Origanum vulgare*, *Thymus vulgare* and *Mentha piperita*.

3. Pharmaceutical composition according to claim 1 or 2, characterized in that the active agent is at least an oil extracted from *Origanum vulgare* and optionally *Thymus vulgare*.

4. Pharmaceutical composition according to any of claims 1-3, characterized in that the pharmaceutical carrier is of a natural origin.

5. Pharmaceutical composition according to claim 4, characterized in that the pharmaceutical carrier is selected from the group consisting of lactose, honey, laurel, vaselin, paraffin, starch products and calcium carbonate.

6. Pharmaceutical composition according to any of the claims 1-5, characterized in that the active agent is present in an amount of 1-15% by weight, calculated on the total weight of the composition.

7. Pharmaceutical composition according to claim 6, characterized in that the active agent is present in an amount of 4-10% by weight, calculated on the total weight of the composition.


8. Pharmaceutical composition according to any of the claims 1-7, characterized in that said composition, in particular veterinary compositions, contain tannin.

9. Pharmaceutical composition according to claim 8, characterized in that the tannin content of the composition is

0.5-2.5% by weight, calculated on the total weight of the composition.

10. Use of the composition according to any of the claims 1-9 for both human and veterinary application, in particular the diseases mentioned in the application.

11. A process for recovering oil from the plants defined in claims 1-9, characterized by distilling dry parts and blossoms of said plants with the help of water vapour at a temperature of about 100°C.





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 35/78		A3	(11) International Publication Number: WO 96/37210
			(43) International Publication Date: 28 November 1996 (28.11.96)
(21) International Application Number: PCT/NL96/00210		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 24 May 1996 (24.05.96)		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(30) Priority Data: 950075 26 May 1995 (26.05.95) MK 950076 26 May 1995 (26.05.95) MK			
(71) Applicant (for all designated States except US): ROPAPHARM B.V. I.O. [NL/NL]; Elementenstraat 19-21, NL-1014 AR Amsterdam (NL).		(88) Date of publication of the international search report: 6 February 1997 (06.02.97)	
(72) Inventor; and			
(75) Inventor/Applicant (for US only): NINKOV, Dusan [-/NL]; Punter 14, NL-1186 RC Amstelveen (NL).			
(74) Agent: DE BRUIJN, Leendert, C.; Nederlandsch Octrooibureau, Scheveningseweg 82, P.O. Box 29720, NL-2502 LS The Hague (NL).			

(54) Title: PHARMACEUTICAL COMPOSITIONS, BASED ON ETHERIC OILS OBTAINED FROM PLANTS FOR USE IN THE HUMAN AND VETERINARY MEDICAL FIELD

(57) Abstract

The invention relates to pharmaceutical compounds which are based on the anti-inflammatory properties of etheric oils selected from the group consisting of *Origanum vulgare*, *Thymus vulgaris*, *Mentha piperita*, *Thymus serpyllum*, *Saturea hortensis*, *Saturea montana*, *Saturea subricata*, *Carum corticum*, *Thymus zygis*, *Ocimum gratissimum*, *Moranda pungtata*, *Mosla japonica* and *Salvia officinalis*. Preferably the etheric oils, obtained at the distillation of *Origanum vulgare*, *Thymus vulgaris* and/or *Mentha piperita* are used. Such pharmaceutical compounds, compared to synthetic sulfonamids, antibiotics and cortisones do not create biorecipients in the human body as well as in animal meat and milk and do not contribute to the resistance of microorganism against pharmaceutical compositions in general. The composition according to the invention can be used in the treatment of colibacillosis, dermatomycosis, lice, perspiration and fungus on feet, dermatitis, acne and of veterinary diseases like coccidiosis, mastitis, etc.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Larvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

INTERNATIONAL SEARCH REPORT

International Application No
PCT/NL 96/00210

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K35/78

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ANNALES PHARMACEUTIQUES FRANCAISES, vol. 43, no. 1, 1985, PARIS FR, pages 77-81, XP000602033 JEAN-CLAUDE GUARIN ET AL.: "ACTIVITA ANTIFONGIQUE D'EXTRAITS VAGATAUX À USAGE THARAPEUTIQUE.II. ATUDE DE 40 EXTRAITS SUR 9 SOUCHES FONGIQUES." see the whole document ---	1-3
X	CHROMATOGRAPHIA, vol. 30, no. 1/2, July 1990, pages 16-23, XP000566858 M. ONDARZA ET AL.: "STEAM DISTILLATION AND SUPERCRITICAL FLUID EXTRACTION OF SOME MEXICAN SPICES." see the whole document ---	11
	-/--	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

2 October 1996

Date of mailing of the international search report

20.12.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

REMPP, G

INTERNATIONAL SEARCH REPORT

International Application No PCr/NL 96/00210
--

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FR 2 706 770 A (PELLETIER JACQUES) 30 December 1994 see the whole document -----	1-10

4

INTERNATIONAL SEARCH REPORT

International application No.

PCT/NL 96/00210

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 10
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 10 is directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see continuation-sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-11 all partially

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/210

1. Claims:1-11 All partially:-Pharmaceutical composition containing as active agent at least one oil extracted from the *Origanum* plant genus, possibly in combination with an oil extracted from another plant as cited in claim 1, its use and its recovery process.

2. Claims:1-11 All partially:-Pharmaceutical composition containing as active agent at least one oil extracted from the *Thymus* plant genus, possibly in combination with an oil extracted from another plant as cited in claim 1 and as far as it is not covered by invention 1, its use and its recovery process.

3. Claims 1,2,4-11 All partially:-Pharmaceutical composition containing as active agent at least one oil extracted from the *Mentha* plant genus, possibly in combination with an oil extracted from another plant as cited in claim 1 and as far as it is not covered by the previous inventions, its use and its recovery process.

4. Claims 1,4-11 All partially:-Pharmaceutical composition containing as active agent at least one oil extracted from the *Saturea* plant genus, possibly in combination with an oil extracted from another plant as cited in claim 1 and as far as it is not covered by the previous inventions, its use and its recovery process.

5. Claims 1,4-11 All partially:-Pharmaceutical composition containing as active agent at least one oil extracted from the *Carum* plant genus, possibly in combination with an oil extracted from another plant as cited in claim 1 and as far as it is not covered by the previous inventions, its use and its recovery process.

6. Claims 1,4-11 All partially:-Pharmaceutical composition containing as active agent at least one oil extracted from the *Ocimum* plant genus, possibly in combination with an oil extracted from another plant as cited in claim 1 and as far as it is not covered by the previous inventions, its use and its recovery process.

7. Claims 1,4-11 All partially:-Pharmaceutical composition containing as active agent at least one oil extracted from the *Moranda* plant genus, possibly in combination with an oil extracted from another plant as cited in claim 1 and as far as it is not covered by the previous inventions, its use and its recovery process.

8. Claims 1,4-11 All partially:-Pharmaceutical composition containing as active agent at least one oil extracted from the *Mosia* plant genus, possibly in combination with an oil extracted from another plant as cited in claim 1 and as far as it is not covered by the previous inventions, its use and its recovery process.

9. Claims 1,4-11 All partially:-Pharmaceutical composition containing as active agent at least one oil extracted from the *Salvia* plant genus, possibly in combination with an oil extracted from another plant as cited in claim 1 and as far as it is not covered by the previous inventions, its use and its recovery process.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/NL 96/00210

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR-A-2706770	30-12-94	NONE	

Form PCT/ISA/210 (patent family annex) (July 1992)

